MA45177B1 - Traitement de la maladie de parkinson - Google Patents

Traitement de la maladie de parkinson

Info

Publication number
MA45177B1
MA45177B1 MA45177A MA45177A MA45177B1 MA 45177 B1 MA45177 B1 MA 45177B1 MA 45177 A MA45177 A MA 45177A MA 45177 A MA45177 A MA 45177A MA 45177 B1 MA45177 B1 MA 45177B1
Authority
MA
Morocco
Prior art keywords
alkyl
hydrogen
parkinson
disease treatment
halo
Prior art date
Application number
MA45177A
Other languages
English (en)
Other versions
MA45177A (fr
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Priority claimed from PCT/IN2017/050224 external-priority patent/WO2017208267A1/fr
Publication of MA45177A publication Critical patent/MA45177A/fr
Publication of MA45177B1 publication Critical patent/MA45177B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de traitement ou de prévention de la maladie de parkinson chez un sujet, comprenant l'administration d'un composé de formule i dans laquelle r1 est -nhc(o)(cycloalkyle en c3-6) et r2 est hydrogène ; ou r1 et r2, conjointement avec les atomes de carbone auxquels ils sont liés, forment un cycle aromatique à six chaînons, le cycle étant substitué par un ou plusieurs groupes choisis parmi hydrogène, halogène et alkyle en c1-6 ; r3 et r4 sont indépendamment choisis dans le groupe comprenant hydrogène, halogène, alkyle en c1-3, o(alkyle en c1- 3), no2, s(alkyle en c1-3), halogénoalkyle en c1-3, o(halogénoalkyle en c1-3) et s(halogénoalkyle en c1-3) ; ou un sel pharmaceutiquement acceptable de celui-ci.
MA45177A 2016-06-02 2017-06-02 Traitement de la maladie de parkinson MA45177B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (fr) 2016-06-02 2017-06-02 Traitement de la maladie de parkinson

Publications (2)

Publication Number Publication Date
MA45177A MA45177A (fr) 2019-04-10
MA45177B1 true MA45177B1 (fr) 2022-08-31

Family

ID=83280007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45177A MA45177B1 (fr) 2016-06-02 2017-06-02 Traitement de la maladie de parkinson

Country Status (1)

Country Link
MA (1) MA45177B1 (fr)

Also Published As

Publication number Publication date
MA45177A (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
JOP20230235A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
PH12018502457A1 (en) Treatment for parkinson's disease
JP2015143283A5 (fr)
RU2012101947A (ru) Способы лечения и профилактики усталости
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
JP2012041365A5 (fr)
JP2013010792A5 (fr)
MX388641B (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
JP2019520344A5 (fr)
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
BRPI0616659A8 (pt) droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
MX2021009045A (es) Moduladores de transporte nuclear que contienen acrilo y uso de los mismos.
MA45177B1 (fr) Traitement de la maladie de parkinson
MA56324B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EA202190406A1 (ru) Способы лечения нейродегенеративных расстройств
JP2007507467A5 (fr)
EA201892640A1 (ru) Лечение болезни паркинсона
JP2018534350A5 (fr)
BR112021024398A2 (pt) Processo alternativo para a preparação de ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-di-hidropirimidin-6-il]metil]-3-oxo-5,6,8,8a-tetra-hidro-1h-imidazo[1,5-a]pirazin-2-il]-carboxílico
BR112021012082A8 (pt) Formas deuteradas e derivados de volinanserina
EA202190724A1 (ru) Препарат на основе кетамина для лечения депрессий путём ингаляций